CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr. Raje on bb21217 in Multiple Myeloma

March 15th 2019

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses preliminary data on bb21217 in multiple myeloma.

What's Keeping CAR T-Cell Therapies From the Outpatient Setting?

March 13th 2019

Although these therapies were initially conceived of and developed as inpatient therapies, interest is growing in extending chimeric antigen receptor T-cell therapies to the outpatient setting.

Dr. Kambhampati on the Potential of CAR T-Cell Therapy in CLL

March 8th 2019

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL).

Dr. Park Discusses Use of CAR T Cells in ALL

March 5th 2019

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the use of CAR T cells in the treatment of patients with acute lymphoblastic leukemia.

CD30 CAR T Cells Active in Hodgkin Lymphoma

February 25th 2019

Chimeric antigen receptor T cells targeting CD30 proved to be safe and active in relapsed/refractory Hodgkin lymphoma.

Dr. Maziarz on Sustained Responses With Tisagenlecleucel in DLBCL

February 20th 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses sustained responses with tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.

CMS Proposes Coverage With Evidence Development for CAR T-Cell Therapy for Cancers

February 19th 2019

The Centers for Medicare & Medicaid Services has proposed to cover chimeric antigen receptor T-cell therapies approved by the FDA, under “Coverage with Evidence Development."

Ibrutinib/JCAR014 Combo Shows Potential in Relapsed/Refractory CLL

February 13th 2019

Jordan Gauthier, MD, MSc, discusses retrospective results of concurrent ibrutinib and JCAR014 and where chimeric antigen receptor T-cell research is headed for patients with chronic lymphocytic leukemia.

Dr. Ghobadi on the Safety of CAR T-Cell Therapy in Hematologic Malignancies

February 13th 2019

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the safety of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies.

Following Progression on CAR T-Cell Therapy, B-Cell Lymphoma Treatment Options Needed

February 12th 2019

Victor A. Chow, MD, discusses the next steps in understanding how to treat patients with large B-cell lymphomas who progress after chimeric antigen receptor T-cell therapy.

Dr. Holstein Discusses Mechanism of bb21217 in Myeloma

February 9th 2019

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses the mechanism of action for bb21217 in the treatment of patients with myeloma.

Dr. Shah on the Curative Potential of CAR T-Cell Therapy in Myeloma

February 8th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the curative potential of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Maziarz Discusses Promise of Tisagenlecleucel in DLBCL

February 2nd 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses the promise of tisagenlecleucel in the treatment of patients with diffuse large B-cell lymphoma.

NICE Recommends Tisagenlecleucel for Relapsed/Refractory DLBCL

February 1st 2019

The UK’s National Institute for Health and Care Excellence has authorized the use of the CAR T-cell therapy tisagenlecleucel (Kymriah) for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma who have received ≥2 lines of chemotherapy.

Lead Investigator Says Tisagenlecleucel Has Changed Natural History of DLBCL

January 23rd 2019

Richard T. Maziarz, MD, discusses the updated findings from JULIET and their clinical implications for patients with diffuse large B-cell lymphoma.

Dr. Ghobadi Discusses the Logistics of CAR T-Cell Therapy

January 23rd 2019

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the logistics of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Andreadis Discusses FDA-Approved CAR T-Cell Therapies in DLBCL

January 18th 2019

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses FDA-approved chimeric antigen receptor (CAR) T-cell therapies in diffuse large B-cell lymphoma (DLBCL).

Dr. Shah Discusses Challenges With CAR T-Cell Therapy in Myeloma

January 15th 2019

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses challenges with chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Dr. Goy Discusses the Cost of CAR T-Cell Therapy

January 12th 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the cost of chimeric antigen receptor (CAR) T-cell therapy.

Following bb2121, Novel CAR T-Cell Product Shows Potential in Myeloma

January 12th 2019

Nina Shah, MD, discusses the promise of bb21217 in the complex treatment paradigm of relapsed/refractory multiple myeloma